S100A6 (S100 calcium binding protein A6)

Univariate ROC analyses identified S100A6+ plasmacytoid DCs, S100A8+ plasmacytoid DCs, and CD14+CD86+S100A8+ monocytes as candidate PDAC-associated immune features. However, further validation incorporating benign pancreatic conditions and multivariable modeling is required before conclusions can be drawn regarding diagnostic specificity and clinical applicability.

Our findings highlight the potential of lactylation-related biomarkers to enhance CRC prognostic prediction and therapeutic stratification, providing new insights into immune modulation and chemoresistance. This study underscores the importance of incorporating lactylation features into CRC molecular profiling to improve personalized treatment strategies.

The high expression of LAD1 in cancer cells, its associations with LUAD-related genes, and its links to biological processes and pathways suggest its potential biological relevance and that it merits further investigation. Overall, this study provides insights into LUAD and supports LAD1 as a gene worthy of further investigation.

Additionally, TNX05II was significantly resistant to α-glucosidase degradation. This study suggests a possible key structure-target relationship underlying TNX05's antitumor activity, providing a molecular basis for the antitumor mechanism of Arisaema polysaccharides.

Immunofluorescent double staining was used to examine the co-expression of CD31 in α-SMA-positive CAFs to identify whether the endothelial-to-mesenchymal transition (EndoMT) is involved in the origin, and obvious colocalization was observed. Visium and Visium HD spatial transcriptomics further revealed endothelial cells (ECs) exhibited remarkable co-expression of CAF-specific marker genes and revealed inferred developmental trajectories to CAFs; molecular determinants, including TIMP1, IGFBP7, THBS2, CD74, COL4A1, COL4A2, AEBP1, S100A6, KCTD12, CALD1, IGHG1, SERPINE1, MCL1, MGP, GSTP1, TAGLN, THBS1, and CTGF, were positively correlated with the spatial developmental trajectories of ECs to CAFs; and CTGF exhibited extensive interactions with other common positively correlated molecular determinants and was a highly connected node in the interaction network. ECs that undergo EndoMT may be one of the potential cellular and mechanical origins of CAFs in HCC, and the development of EndoMT may be associated with CTGF.

Lactylation defines distinct tumor cell clusters in GBM that are spatially localized, metabolically reprogrammed, and immunosuppressive. The S100A6-associated lactylation signature serves as a robust prognostic biomarker and potential therapeutic target in GBM.

Beyond IRI and inflammatory reactions, RAGE has been implicated in a range of other diseases, positioning it as a potential therapeutic target for multiple conditions. This article provides a comprehensive assessment of RAGE and its possible involvement in the onset and progression of diseases affecting various organs and systems, while also briefly summarizing both existing and novel therapeutic targets for prevention or intervention related to RAGE.

However, there is no obvious difference in the inhibitory rate of cisplatin (2.5µg/mL 24h; 10µg/mL 24h, 48h; 5µg/mL, 20µg/mL, 40µg/mL 24h, 48h, and 72h), pemetrexed, bevacizumab on two groups. Our results demonstrated that S100A6 can apparently promote the resistance to gefitinib of LADC PC9 cell lines with EGFR 19 exon mutations.

Our results suggested that CACYBP expression in HCC is associated with enhanced cell proliferation and cell cycle progression, as well as altered metabolic and immune responses, which contribute to the poorer clinical and survival outcomes of patients.

In this study, we also identified many splicing alterations in cancer-related genes, with castration resistance-induced alternative splicing events closely related to the interaction networks of regulation of cell cycle process, cell division, and regulation of cell projection organization. Our research findings suggest that S100A6 may serve as a molecular marker or therapeutic target associated with castration resistance in prostate cancer, providing new insights into the molecular basis of this disease.